INSTITUT CLAUDIUS REGAUD
🇫🇷France
Clinical Trials
124
Active:17
Completed:52
Trial Phases
5 Phases
Phase 1:18
Phase 2:20
Phase 3:8
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (104 trials with phase data)• Click on a phase to view related trials
Not Applicable
52 (50.0%)Phase 2
20 (19.2%)Phase 1
18 (17.3%)Phase 3
8 (7.7%)Phase 4
6 (5.8%)Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers
Not Applicable
Not yet recruiting
- Conditions
- Early Breast CancerMetastatic Breast Cancer
- First Posted Date
- 2025-11-18
- Last Posted Date
- 2025-11-18
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 1050
- Registration Number
- NCT07233928
- Locations
- 🇫🇷
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.
Not Applicable
Recruiting
- Conditions
- Locally Advanced or Metastatic Breast Cancers
- Interventions
- Biological: Pharmacokinetics blood samples
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-11-18
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 210
- Registration Number
- NCT07195344
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest - Site Angers, Angers, France
🇫🇷Centre Georges François Leclerc, Dijon, France
🇫🇷Institut Paoli Calmettes, Marseille, France
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
Not Applicable
Recruiting
- Conditions
- Urothelial CarcinomaRenal CancerProstate AdenocarcinomaAdenocarcinoma of EndometriumCutaneous MelanomaSoft Tissue Sarcoma (STS)Nonseminomatous Germ Cell TumorSeminomatous Germ Cell TumorUpper Aerodigestive Tract CarcinomaCervical Carcinoma
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 450
- Registration Number
- NCT06967961
- Locations
- 🇫🇷
Oncopole Claudius Regaud, IUCT-O, Toulouse, France
Prostate Cancer Burden and Heterogeneity Evaluation Towards Liquid Biopsy: a Correlation Study to 18FDCFPyL PET and Patients Outcome
Not Applicable
Recruiting
- Conditions
- Prostate Cancer
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-11-18
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 80
- Registration Number
- NCT06917781
- Locations
- 🇫🇷
IUCT-O, Toulouse, France
Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
Not Applicable
Recruiting
- Conditions
- Metastatic Breast CancerMetastatic Prostate Cancer
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 36
- Registration Number
- NCT06904625
- Locations
- 🇫🇷
IUCT-O, Toulouse, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 23
- Next
News
Breakthrough Breast Cancer Drug Capivasertib Approved for NHS Use
A groundbreaking twice-daily pill called capivasertib (Truqap) has been approved for NHS use, targeting hormone receptor-positive HER2-negative breast cancer by blocking cancer growth mechanisms.